Skip to main content

Advertisement

SpringerLink
Log in

Effects of Amantadine Sulfate on Cognitive Impairments in Patients with Parkinson’s Disease

  • Published:
Neuroscience and Behavioral Physiology Aims and scope Submit manuscript

Cognitive impairments in patients with Parkinson’s disease (PD) lead to occupational, social, and psychological maladaptation of patients and their relatives. This article presents the epidemiology, structure, and nature of cognitive impairments in PD; the main pathogenetic factors involved in the development of moderate cognitive impairment and dementia in PD are discussed, as are the methods of diagnosis and assessment of cognitive impairments and approaches to the correction of memory and intellectual impairments. Results obtained from our own studies of the effects of treatment with amantadine sulfate at a dose of 300 mg for 6 months on changes in cognitive impairments in 25 patients with PD are presented. Treatment results were evaluated using neuropsychological questionnaire and scales (Mini Mental State Evaluation, Frontal Assessment Battery, Matiss Dementia Rating Scale). In patients with PD and moderate cognitive impairments, six months of treatment with amantadine sulfate produced significant improvements in neuropsychological test results.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. R. K. Arakelyan, E. A. Nerobkova, and E. A. Katunina, “Functional activity of the brain in patients with Parkinson’s disease during treatment with amantadine sulfate,” Zh. Nevrol. Psikhiat., 4 (2005).

  2. D. V. Artemiev and Zh. M. Glozman, “Impairments to higher mental functions in Parkinson’s disease,” in: Progress in Neurogeriatrics [in Russian], N. N. Yakhno and I. V. Damulin (eds.), Moscow (1995), Vol. 1, pp. 46–58.

  3. I. V. Damulin, Dementia in Parkinson’s Disease. Advice for Physicians [in Russian], Moscow (2005).

  4. V. V. Zakharov, “Dementia in Parkinson’s disease,” Nevrol. Zh., Addendum 1, 11, 13–18 (2006).

    Google Scholar 

  5. V. V. Zakharov, Impairments to Cognitive Functions in Parkinson’s Disease and Symptomatic Parkinsonism [in Russian], Author’s Abstract of Doctoral Thesis in Medical Sciences, Moscow (2003), pp. 36–40.

  6. V. V. Zakharov, P. V. Yaroslavtseva, and N. N. Yakhno, “Cognitive impairments in Parkinson’s disease,” Nevrol. Zh., 2, 11–13 (2003).

    Google Scholar 

  7. V. V. Zakharov and N. N. Yakhno, “Moderate cognitive impairment in the elderly: diagnosis and treatment,” Rus. Med. Zh., 10, 573–576 (2004).

    Google Scholar 

  8. O. S. Levin, L. A. Batukaeva, and I. G. Smolentseva, “Diagnosis and treatment of dementia in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 6, 91–97 (2008).

    Google Scholar 

  9. O. S. Levin and L. V. Golubeva, “Heterogeneity of moderate cognitive impairment: diagnostic and therapeutic aspects,” Konsilium, 12, 106–110 (2006).

    Google Scholar 

  10. ICD-10. International Classification of Diseases and Health- Related Problems [Russian translation], 10th edition, Vol. 1, WHO, Geneva (1995).

  11. A. A. Pilipovich and V. L. Golubev, “Effects of Pronoran on cognitive and affective impairments in Parkinson’s disease,” Zh. Nevrol. Psikhiat., 4, 41–47 (2005).

    Google Scholar 

  12. A. N. Sadikova, Correction of Clinical, Neuropsychological, and Computerized Tomography Data in Parkinson’s Disease [in Russian], Author’s Abstract of Master’s Thesis in Medical Sciences, Moscow (1977).

  13. A. D. Stepkina, V. V. Zakharov, and N. N. Yakhno, “Cognitive impairments on progression of Parkinson’s disease,” Zh. Nevrol. Psikhiat., 10, 13–19 (2005).

    Google Scholar 

  14. N. N. Yakhno, Cognitive impairments in the neurology clinic,” Nevrol. Zh., Addendum 1, 11, 4–12 (2006).

    Google Scholar 

  15. A. L. Benton, N. R. Varney, and K. Hamsher, “Visuospatial judgement: a clinical test,” Arch. Neurol., 35, 364–367 (1978).

    PubMed  CAS  Google Scholar 

  16. K. Bronnick, M. Emre, R. Lane, et al., “Profile of cognitive impairment in dementia associated with Parkinson’s disease compared with Alzheimer’s disease,” J. Neurol. Neurosurg. Psychiat., 78, 1064–1068 (2007).

    Article  PubMed  Google Scholar 

  17. P. Caspar, C. Duyckaerts, et al., “Alterations of dopaminergic and noradrenergic innervations in motor cortex in Parkinson’s disease,” Ann. Neurol., 30, 365–374 (1991).

    Article  Google Scholar 

  18. J. L. Cummings, “Cholinesterase inhibitors for treatment of dementia associated with Parkinson’s disease,” J. Neurol. Neurosurg. Psychiat., 76, 903–904 (2005).

    Article  PubMed  CAS  Google Scholar 

  19. B. Dubois, A. Slachevsky, I. Litvan, and B. Pillon, “The FAB: a frontal assessment battery at bedside,” Neurology, 55, 1621–1626 (2000).

    PubMed  CAS  Google Scholar 

  20. M. Emre, D. Aarsland, R. Brown, et al., “Clinical diagnostic criteria for dementia associated with Parkinson’s disease,” Mov. Dis., 22, 1689–1707 (2007).

    Article  Google Scholar 

  21. M. Emre, “Dementia associated with Parkinson’s disease,” Lancet Neurol., 2, 229–237 (2003).

    Article  PubMed  CAS  Google Scholar 

  22. S. Fahn and R. Eiton, Unified Parkinson’s Disease Rating Scale. Recent Developments in Parkinson’s Disease, S. Fahn, C. Marsden, and D. Calne (eds.), McMillan Healthcare Information (1987), Vol. 5, pp. 153–163.

  23. M. F. Folstein, S. E. Folstein, and P. R. McHugh, “Mini Mental State: a practical guide for grading the mental state of patients for the clinician,” J. Psychiatr. Res., 12, 189–198 (1975).

    Article  PubMed  CAS  Google Scholar 

  24. J. E. Galvin, J. Pollack, and J. C. Morris, “Clinical phenotype of Parkinson Disease dementia,” Neurology, 67, 1605–1611 (2006).

    Article  PubMed  Google Scholar 

  25. G. Gianutsos, S Chute, and J. P. Dunne, “Pharmacological changes in dopaminergic systems induced by long-term administration of amantadine,” Eur. J. Pharmacol., 110, 357–361 (1985).

    Article  PubMed  CAS  Google Scholar 

  26. J. Golomb, A. Kluger, and S. H. Ferris, Clinician’s Manual on Mild Cognitive Impairment, Science Press, London (2001).

    Google Scholar 

  27. P. Hobson and J. Meara, “Risk and incidence of dementia in a cohort of older subjects with Parkinson’s disease in the United Kingdom,” Mov. Dis., 19, 1043–1049 (2004).

    Article  Google Scholar 

  28. M. Hoehn and M. D. Yahr, “Parkinsonism: onset, progression and mortality,” Neurology, 17, No. 5, 427–442 (1967).

    PubMed  CAS  Google Scholar 

  29. R. Inzelberg, U. Bonuccelli, et al., “Association between amantadine and the onset of dementia in Parkinson’s disease,” Mov. Dis., 2, No. 9, 1375–1379 (2006).

    Article  Google Scholar 

  30. D. M. Jacobs, K. Marder, L. Cote, et al., “Neuropsychological characteristics of preclinical dementia in Parkinson’s disease,” Neurology, 45, 1691–1696 (1995).

    PubMed  CAS  Google Scholar 

  31. J. Kaplan, H. Goodglass, and S. Weintraub, The Boston Naming Test, Boston (1978).

  32. P. L. Le Bars, M. M. Katz, and N. A. Berman, “Placebo-controlled, double-blind, randomized trial of an extract of Gingko biloba for dementia,” J. Am. Med. Assoc., 278, 1327–1332 (1997).

    Article  Google Scholar 

  33. G. Lewy and D. M. Jacobs, “Memory and executive function impairments predict dementia in Parkinson’s disease,” Mov. Dis., 17, No. 6, 1221–1226 (2002).

    Article  Google Scholar 

  34. M. D. Lezak, Neuropsychology Assessment, New York University Press, New York (1983).

    Google Scholar 

  35. M. A. Malone, K. Jerchner, and J. M. Swanson, “Hemispheric processing and methylphenidate effects in attention deficit hyperactivity disorder,” J. Child Neurol., 9, No. 2, 181 (1997).

    Article  Google Scholar 

  36. K. Marder, M. Z. Tang, L. Cote, and Y. Stern, “The frequency and associated risk factors for dementia in patients with Parkinson’s disease,” Arch. Neurol., 52, 695–701 (1995).

    PubMed  CAS  Google Scholar 

  37. S. Mattis, “Mental state examination for organic mental syndrome in the elderly patient,” in: Geriatric Psychiatry, L. Bellack and T. B. Karasu (eds.), New York (1976).

  38. K. Palmer,V. Jelic, and B. Winblad, “Preface: mild cognitive impairment,” Acta Neurol. Scand., 107, Supplement 179, 5–6 (2003).

    Article  Google Scholar 

  39. R. F. Peppard. W. R. Martin, G. D. Carr, et al., “Cerebral glucose metabolism in Parkinson’s disease with and without dementia,” Arch. Neurol., 49, 1262–1268 (1992).

    PubMed  CAS  Google Scholar 

  40. R. S. Peterson, G. E. Smith, S. C. Waring, et al., “Mild cognitive impairment: clinical characterization and outcome,” Arch. Neurol., 56, 303–308 (1999).

    Article  Google Scholar 

  41. R. S. Peterson and J. Touchon, “Consensus on mild cognitive impairment,” Res. Pract. Alzheimer’s Dis., 10, 24–32 (2005).

    Google Scholar 

  42. W. Poewe, E. Wolters, M. Emre, et al., “Long-term benefits of rivastigmine in dementia associated with Parkinson’s disease: an active treatment extension study,” Mov. Dis., 21, No. 4, 456–461 (2006).

    Article  Google Scholar 

  43. P. R. von Voigtlander and K. E. Moore, “Dopamine release from the brain in vivo by amantadine,” Science, 174, 408–410 (1937).

    Article  Google Scholar 

  44. A. R. Young et al., in: Excitatory Amino Acids and Synaptic Transmission, Academic Press Harcourt Brace and Co., New York, pp. 29–40.

Download references

Author information

Authors and Affiliations

  1. Department of Neurology, Russian Postgraduate Medical Academy, Moscow, Russia

    A. Yu. Yablonskaya, N. V. Fedorova & M. E. Belgusheva

  2. Center for Extrapyramidal Studies, Moscow, Russia

    N. V. Fedorova

Authors
  1. A. Yu. Yablonskaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. V. Fedorova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. E. Belgusheva
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

Translated from Zhurnal Nevrologii i Psikhiatrii imeni S. S. Korsakova, Vol. 110, No. 7, pp. 24–30, July, 2010.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Yablonskaya, A.Y., Fedorova, N.V. & Belgusheva, M.E. Effects of Amantadine Sulfate on Cognitive Impairments in Patients with Parkinson’s Disease. Neurosci Behav Physi 41, 567–573 (2011). https://doi.org/10.1007/s11055-011-9456-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11055-011-9456-z

KEY WORDS

Search

Navigation